Chronic hepatitis B virus infection

Med Clin North Am. 2014 Jan;98(1):39-54. doi: 10.1016/j.mcna.2013.08.004. Epub 2013 Oct 20.

Abstract

All providers, regardless of specialty, should perform screening for HBV on high-risk persons, especially those born in endemic countries. The primary care physician can perform the initial evaluation and follow-up of patients with chronic HBV by following the algorithm in this article and consulting with specialists when appropriate. Chronically infected patients should be followed on a regular basis, preferably every 6 months, with liver function tests, and when appropriate, HBV DNA levels. Those who meet the criteria for high risk for HCC should undergo liver ultrasound every 6 months. Powerful antiviral medications are available that can suppress but not cure HBV and result in resolution of liver inflammation and fibrosis, even cirrhosis, as well as decrease the risk of developing HCC. They should be used in those patients who meet the criteria outlined in the practice guidelines of the major liver societies.

Keywords: Chronic hepatitis B; Management; Natural history.

Publication types

  • Review

MeSH terms

  • Alanine Transaminase / blood
  • Antiviral Agents / classification
  • Antiviral Agents / therapeutic use
  • Biopsy
  • Carcinoma, Hepatocellular* / diagnosis
  • Carcinoma, Hepatocellular* / etiology
  • Carcinoma, Hepatocellular* / prevention & control
  • DNA, Viral / blood*
  • Disease Management
  • Hepatitis B Antibodies / blood
  • Hepatitis B Surface Antigens / blood
  • Hepatitis B virus* / drug effects
  • Hepatitis B virus* / immunology
  • Hepatitis B, Chronic* / complications
  • Hepatitis B, Chronic* / drug therapy
  • Hepatitis B, Chronic* / epidemiology
  • Hepatitis B, Chronic* / immunology
  • Humans
  • Immunocompromised Host / immunology
  • Liver Cirrhosis* / diagnosis
  • Liver Cirrhosis* / etiology
  • Liver Cirrhosis* / prevention & control
  • Liver Neoplasms* / diagnosis
  • Liver Neoplasms* / etiology
  • Liver Neoplasms* / prevention & control
  • Mass Screening / organization & administration
  • Monitoring, Immunologic
  • Monitoring, Physiologic / methods

Substances

  • Antiviral Agents
  • DNA, Viral
  • Hepatitis B Antibodies
  • Hepatitis B Surface Antigens
  • Alanine Transaminase